Dietary supplementation with gamma-linolenic, linoleic and oleic acids decreases PPAR-gamma expression and helps the tetracycline derivative to reduce NOD2 expression in patients with acne vulgaris

Dear Editor,

Acne vulgaris (AV) is an immunoinflammatory dermatosis of the sebaceous glands (SG), inter-adnexal epithelium (IE) and hair follicles (HF); it shows lipid synthesis and cytokine expression by microorganism-cell interaction. In AV, toll-like receptors type 2 (TLR2) and 4 (TLR4), nucleotide oligomerization domain-like type 1 (NOD1) and 2 (NOD2) and peroxisome proliferator-activated receptor gamma (PPARG) regulate the SG expression, cell differentiation and macronutrient metabolism. Dietary fatty acids (FAs) seem to influence AV through the imbalance of omega-3 and -6 FAs. Our hypothesis is that supplementation with gamma linolenic (GLA), linoleic (AL) and oleic (OA) acids, with or without tetracycline (LM), interferes with the expression of TLR1, TLR2, NOD1, NOD2, and PPARG in AV.

The present research was an open, prospective, randomized, non-placebo-controlled study, approved by the Research Ethics Committee of Pontifícia Universidade Católica de Campinas (PUC-Campinas; protocol n. 387/09) and Faculdade de Medicina da Universidade de São Paulo (FMUSP; 229/10), at the Dermatology Service at PUC-Campinas; FMUSP Department of Dermatology; Exper-

---

**Financial support**

None declared.

**Authors’ contributions**

Felipe Bochnia Cerci: Participation in the design and planning of the study; collection, analysis, and interpretation of data; writing; critical review of the manuscript; approval of the final version.

Stanislav Tolkachjov: Writing; critical review of the manuscript; approval of the final version.

Betina Werner: Writing; critical review of the manuscript; approval of the final version.

**Conflicts of interest**

None declared.

**References**

1. Cerci FB. ‘Dermoscopy’ mapping: correlating dermoscopic findings with histology in Mohs micrographic surgery. J Eur Acad Dermatol Venereol. 2018;32:343–4.
2. Jayasekera PS, Dodd J, Oliphant T, Langtry JAA, Lawrence CM. Dermoscopy prior to Mohs micrographic surgery does not improve tumour margin assessment and leads to fewer Mohs stages. Br J Dermatol. 2018;178:565–6.
3. Shin K, Kim H-J, Ko H-C, Kim B-S, Kim M-B, Kim H-S. Dermoscopy-guided Mohs micrographic surgery in post-laser basal cell carcinomas: is dermoscopy helpful for demarcation of the surgical margin? J Dermatolog Treat. 2021;1–4.
4. Suzuki HS, Serafini SZ, Sato MS. Utility of dermoscopy for demarcation of surgical margins in Mohs micrographic surgery. An Bras Dermatol. 2014;89:38–43.
5. Terushkin V, Wang SQ. Mohs surgery for basal cell carcinoma assisted by dermoscopy: report of two cases. Dermatol Surg. 2009;35:2031–5.
6. Yeom SD, Lee SH, Ko HS, Chung KS, Shin J, Choi GS, et al. Effectiveness of dermoscopy in Mohs micrographic surgery (MMS) for nonmelanoma skin cancer (NMSC). Int J Dermatol. 2017;56:136–9.
7. Reiter O, Mimouni I, Dusza S, Halpern AC, Leshem YA, Marghoob AA. Dermoscopic features of basal cell carcinoma and its subtypes: a systematic review. J Am Acad Dermatol. 2019;85:653–64.
8. Suppa M, Micantoni T, Di Stefani A, Soyer HP, Chimenti S, Fargnoli MC, et al. Dermoscopic variability of basal cell carcinoma according to clinical type and anatomic location. J Eur Acad Dermatol Venereol. 2015;29:1732–41.
9. Cerci FB, Kubo EM, Werner B, Tolkachjov SN. Surgical margins required for basal cell carcinomas treated with Mohs micrographic surgery according to tumor features. J Am Acad Dermatol. 2020;83:493–500.
10. Conforti C, Giuffrida R, Zalaudek I, Guarnieri F, Cannavò SP, Pizzichetta MA, et al. Dermoscopic findings in the presurgical evaluation of basal cell carcinoma. A prospective study. Dermatol Surg. 2021;47:37–41.

Felipe Bochnia Cerci, Stanislav N. Tolkachjov, Betina Werner

a Post-graduate Program in Internal Medicine and Health Sciences, Universidade Federal do Paraná, Curitiba, PR, Brazil
b Clínica Cepelle, Curitiba, PR, Brazil
c Epiphany Dermatology, Dallas, TX, United States

Corresponding author. E-mail: felipecerci@ufpr.br (F.B. Cerci).

Received 28 September 2020; accepted 11 November 2020 available online 7 January 2022

https://doi.org/10.1016/j.jabd.2020.11.012
0365-0596/ © 2021 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
imental Pathology Laboratory of Universidade Federal do Rio Grande do Sul (UFRGS); and the Postgraduate Program in Health Sciences at Instituto de Assistência Médica ao Servidor Público Estadual (IAMSP) in São Paulo, resulting in the Doctorate theses of the first and last authors. Financial support was provided by Fundo de Apoio da Sociedade Brasileira de Dermatologia (Funaderm) and a donation of LM (Tetralysal®; 300 mg) and GLA/LA/OA (Tiliv L, 1000 mg; 480 mg/day, 1200 mg/day and 510 mg/day, respectively, of GLA/LA/OA) by Galderma Brasil Ltda., São Paulo, SP, Brazil, and Arese Pharma Ltda., Valinhos, SP, Brazil, respectively.

Forty-five male patients with papulopustular or cystic acne, aged between 13 and 38 years, read, understood, signed the free and Informed Consent Form and were randomized into three therapeutic groups (1:1:1) for 90 days: Group 1, LM 300 mg/day; Group 2, GLA/LA/OA 1000 mg/day; or Group 3, Group 1+Group 2. Papules, pustules and cysts were counted at visits 1, Day 0 (D0); 2, D30; 3, D60; and 4, D90. A biopsy of the papulopustular lesion was performed on D0 and D90 for immunohistochemical analysis of TLR1, TLR2, NOD1, NOD2, and PPARG, evaluated by three pathologists using the following grading score: non-existent (0), weak (1), medium (2) and strong (3).

The means obtained before and after treatment were compared between groups and lesions. Descriptive variables were described by mean and standard deviation, comparing those with a symmetrical distribution by analysis of variance (ANOVA), followed by Tukey’s posthoc; intergroup evaluation was carried out with the Kruskal-Wallis test for non-parametric data; and intragroup evaluation with Wilcoxon test. Descriptive statistics were used, with standard deviation, minimum, maximum, and median values, with a significance level of 5% (p < 0.05) using the statistical package IBM SPSS version 20.

Of the 45 subjects, 36 (80%) completed the study: 11 from Group 1; 13 from Group 2; and 12 from Group 3. There was no statistical difference between the groups (p = 0.626). The ratio of subjects with papulopustular and cystic acne was similar for Groups 1, 2 and 3, and there were no differences regarding phototypes (p = 0.548) and time of disease evolution (p = 0.959; Table 1).

A significant decrease was observed in the number of comedones and cysts throughout the study (p < 0.001), with no difference between the groups and no alterations in comedones and cysts. The pustules decreased significantly (p < 0.001), with no effect of time, difference between the groups (p = 0.049; Table 2). However, the pustules and total AV lesions varied between the study groups (p = 0.049 and p = 0.011; groupVisit interaction; Table 2). There was a decrease in comedones and pustules in all groups and visits when compared to D0, except between D60 and D90 (p = 0.966). For the cysts, there was a decrease, except from D30 on (Table 3).

On immunohistochemistry, there was no difference between the groups and analyzed histopathological sites on D0. On D90, there was a NOD2 difference in the IE between the Groups (Group 1 with higher values than Groups 2 and 3). The median of NOD2 in the IE was two in the three groups, with a maximum value in Group 1 surpassing the others, indicating a somewhat higher distribution of values in Group 1. In the intragroup comparisons, there was a decrease in PPARG in SG in Group 2 (p = 0.016) and a significant increase in NOD2 in HF in Group 1 (p = 0.011; Table 4).

The reduction of inflammatory lesions in the Groups with LM undergoing treatment (Groups 1 and 3) was predicted, as it is one of the tetracyclines of choice in the management of inflammatory AV, with high skin penetration.3,4

Costa et al., in 2007, pointed out a clinical non-response with the use of GLA/LA/OA supplementation, compared to placebo, in AV, but a possible improvement in the SG size, seen in pre-and post-treatment biopsies.5 The present study, however, indicated a possible usefulness of GLA/LA/OA for comedones and cysts, confirming Rustin’s remote assumptions.6

NODs are activated by bacterial muramyl peptidoglycans, combined or not with TLRs. Thus, the result observed in NOD2 may have come from the control of microorganism-

---

### Table 1 Characteristics of subjects with AV included in the study.

| Variables                     | Groups of treatment | p-value |
|-------------------------------|---------------------|---------|
|                               | Group 1 (n = 11)    |         |
| Age (years)                   | 17.5 (3.9)          |         |
| Mean(SD)                      | 17.7 (4.7)          |         |
| Median (Min–Max)              | 16.5 (16 – 31)      |         |
| AV degree                     | 17 (15 – 38)        |         |
| Papulopustular                | 9 (81.8)            |         |
| Cysts                         | 2 (18.2)            |         |
| Phototype                     | 3 (27.2)            |         |
| Phototype                     | 4 (36.4)            |         |
| Phototype                     | 4 (36.4)            |         |
| Phototype                     | 5 (32.8)            |         |
| Mean (SD)                     | 5.3 (2.8)           |         |
| Median (Min–Max)              | 4.5 (2 – 12)        |         |
| p-value                       |                     |         |
| SD, Standard Deviation; Min, Minimum; Max, Maximum; n, Number; p, Probability of observing a result as extreme or more extreme than that of the sample, assuming that the null hypothesis is true; AV, Acne Vulgaris. |
Table 2  Descriptive statistics of lesions according to group and time of treatment.

| Visit | Number of lesions | Group 1 | Group 2 | Group 3 | p-value |
|-------|-------------------|---------|---------|---------|---------|
| D0    | Comedones         | Mean (SD) | 18.4 (5.7) | 23.2 (10.7) | 25.5 (13.0) | 0.328 |
|       |                   | Median (Min–Max) | 18.5 (12 – 29) | 23.0 (5 – 38) | 27.0 (5 – 46) | 0.162 |
|       | Papules           | Mean (SD) | 11.3 (4.9) | 13.6 (4.6) | 14.3 (7.3) | 0.290 |
|       |                   | Median (Min–Max) | 9.5 (6 – 22) | 12.0 (8 – 25) | 12.0 (6 – 35) | 0.496 |
|       | Pustules          | Mean (SD) | 7.3 (4.9) | 10.1 (5.4) | 9.4 (6.5) | 0.156 |
|       |                   | Median (Min–Max) | 8 (2 – 18) | 9 (3 – 22) | 8 (2 – 26) | 0.175 |
|       | Cysts             | Mean (SD) | 1.0 (2.0) | 0.4 (0.9) | 2.9 (5.5) | 0.374 |
|       |                   | Median (Min–Max) | 0 (0 – 6) | 0 (0 – 3) | 0 (0 – 16) | 0.160 |
| D30   | Comedones         | Mean (SD) | 14.8 (4.6) | 18.9 (8.7) | 20.3 (9.1) | 0.142 |
|       |                   | Median (Min–Max) | 14 (8 – 22) | 18 (4 – 32) | 22 (3 – 33) | 0.296 |
|       | Papules           | Mean (SD) | 7.3 (4.2) | 9.5 (3.4) | 8.1 (5.3) | 0.099 |
|       |                   | Median (Min–Max) | 7 (2 – 16) | 9 (4 – 16) | 7 (3 – 24) | 0.022 |
|       | Pustules          | Mean (SD) | 3.8 (3.5) | 5.6 (3.0) | 5.4 (4.4) | 0.149 |
|       |                   | Median (Min–Max) | 3 (0 – 10) | 5.5 (1 – 11) | 4 (0 – 15) | 0.060 |
|       | Cysts             | Mean (SD) | 0.3 (0.9) | 0.0 (0.0) | 1.5 (3.5) | 0.149 |
|       |                   | Median (Min–Max) | 0 (0 – 3) | 0 (0 – 0) | 0 (0 – 12) | 0.033 |
| D60   | Comedones         | Mean (SD) | 26.1 (10.3) | 33.9 (14.0) | 35.4 (15.3) | 0.19 |
|       |                   | Median (Min–Max) | 26.5 (10 – 49) | 31.5 (12 – 57) | 36 (12 – 67) | 0.003 |
|       | Papules           | Mean (SD) | 12.8 (4.0) | 17.5 (9.0) | 15.6 (6.6) | 0.003 |
|       |                   | Median (Min–Max) | 13 (8 – 20) | 16 (4 – 33) | 16 (3 – 26) | 0.003 |
|       | Pustules          | Mean (SD) | 5.1 (2.5) | 8.9 (3.7) | 5.1 (3.9) | 0.003 |
|       |                   | Median (Min–Max) | 5 (1 – 10) | 8.5 (3 – 15) | 5 (0 – 16) | 0.149 |
|       | Cysts             | Mean (SD) | 2.6 (1.9) | 5.6 (3.2) | 2.4 (2.9) | 0.003 |
|       |                   | Median (Min–Max) | 3.5 (0 – 5) | 5 (1 – 12) | 1 (0 – 8) | 0.003 |
| D90   | Comedones         | Mean (SD) | 20.4 (6.7) | 31.9 (12.9) | 23.8 (10.6) | 0.003 |
|       |                   | Median (Min–Max) | 22.5 (9 – 27) | 32.5 (13 – 55) | 25.5 (7 – 43) | 0.19 |
|       | Papules           | Mean (SD) | 11.8 (3.8) | 16.7 (8.0) | 13.4 (6.3) | 0.19 |
|       |                   | Median (Min–Max) | 12 (6 – 20) | 14 (5 – 30) | 12 (3 – 25) | 0.19 |
|       | Pustules          | Mean (SD) | 4.5 (2.7) | 8.4 (4.2) | 3.8 (2.3) | 0.19 |
|       |                   | Median (Min–Max) | 3.5 (1 – 10) | 9 (3 – 18) | 3 (0 – 8) | 0.19 |
|       | Cysts             | Mean (SD) | 2.2 (2.6) | 6.2 (4.1) | 1.6 (1.7) | 0.19 |
|       |                   | Median (Min–Max) | 1.5 (0 – 9) | 7 (1 – 13) | 1 (0 – 4) | 0.003 |
|       | Any lesion        | Mean (SD) | 0.0 (0.0) | 0.0 (0.0) | 0.6 (1.7) | <0.001 |
|       |                   | Median (Min–Max) | 0 (0 – 0) | 0 (0 – 0) | 0 (0 – 6) | <0.001 |
Table 2 (Continued)

| Visit          | Number of lesions | Group 1 | Group 2 | Group 3 | p-value |
|----------------|-------------------|---------|---------|---------|---------|
| Any lesion     |                   |         |         |         |         |
| Mean (SD)      | 18.4 (6.5)        | 31.4 (11.6) | 18.8 (9.0) |         | 0.006   |
| Median (Min–Max)| 18.5 (8 – 27)    | 36 (11 – 48) | 18.5 (6 – 32) |         |         |

SD, Standard Deviation; Min, Minimum; Max, Maximum; n, Number; p, Probability of observing a result as extreme or more extreme than that of the sample, assuming that the null hypothesis is true.

Table 3  Multiple comparisons of numbers of lesions at the visits for the treatment groups.

| Lesion | Comparison | Estimated mean difference | Standard Error | p-value |
|--------|------------|----------------------------|----------------|---------|
| Comedones | D0 vs. D30 | 4.450                      | 0.674          | <0.001 |
|         | D0 vs. D60 | 7.175                      | 1.095          | <0.001 |
|         | D0 vs. D90 | 8.500                      | 1.232          | <0.001 |
|         | D30 vs. D60| 2.725                      | 0.556          | <0.001 |
|         | D30 vs. D90| 4.050                      | 0.748          | <0.001 |
|         | D60 vs. D90| 1.325                      | 0.368          | 0.005  |
| Pustules | D0 vs. D30 | 4.000                      | 0.473          | <0.001 |
|         | D0 vs. D60 | 5.425                      | 0.669          | <0.001 |
|         | D0 vs. D90 | 5.625                      | 0.916          | <0.001 |
|         | D30 vs. D60| 1.425                      | 0.434          | 0.012  |
|         | D30 vs. D90| 1.625                      | 0.702          | 0.113  |
|         | D60 vs. D90| 0.200                      | 0.429          | 0.966  |
| Cysts   | D0 vs. D30 | 0.850                      | 0.224          | <0.001 |
|         | D0 vs. D60 | 1.225                      | 0.301          | <0.001 |
|         | D0 vs. D90 | 1.450                      | 0.352          | <0.001 |
|         | D30 vs. D60| 0.375                      | 0.224          | 0.341  |
|         | D30 vs. D90| 0.600                      | 0.301          | 0.197  |
|         | D60 vs. D90| 0.225                      | 0.224          | 0.747  |

D30, 30 days of study; D60, 60 days of study; D90, 90 days of study; p, Probability of observing a result as extreme or more extreme than that of the sample, assuming that the null hypothesis is true.

Table 4  Comparative table between and within groups for the assessment by the score.

|                | Group 1 (n = 11) | Group 2 (n = 13) | Group 3 (n = 12) | D0 | D90 | P< | D0 | D90 | P< | D0 | D90 | P< | PD0 | PD90 |
|----------------|------------------|------------------|------------------|----|-----|----|----|-----|----|----|-----|----|-----|-----|
| Epithelium     |                  |                  |                  |    |     |    |    |     |    |    |     |    |     |     |
| PPARG          | 2 (0–3)          | 2 (0–3)          | 0.603            | 2 (0–3) | 1 (0–3) | 0.088 | 3 (0–3) | 1 (0–3) | 0.184 | 0.340 | 0.482 |
| NOD1           | 3 (2–3)          | 3 (2–3)          | 0.317            | 3 (2–3) | 3 (1–3) | 0.480 | 3 (1–3) | 3 (1–3) | 0.180 | 0.797 | 0.177 |
| NOD2           | 2 (1–3)          | 2 (1–3)          | 0.063            | 2 (0–3) | 2 (1–2) | 0.102 | 1.5 (0–3) | 2 (1–2) | 0.999 | 0.500 | 0.001 |
| TRL2           | 2 (0–3)          | 2 (1–3)          | 0.317            | 1 (1–3) | 2 (0–3) | 0.480 | 1 (1–3) | 1 (0–3) | 0.739 | 0.370 | 0.794 |
| TRL4           | 1 (0–3)          | 1 (0–2)          | 0.999            | 1 (0–3) | 1 (0–3) | 0.627 | 1 (0–3) | 1 (0–3) | 0.720 | 0.404 | 0.503 |
| Gland Follicle |                  |                  |                  |    |     |    |    |     |    |    |     |    |     |     |
| PPARG          | 2 (1–3)          | 2 (1–3)          | 0.180            | 2 (2–3) | 2 (0–3) | 0.016 | 2 (1–3) | 2 (1–3) | 0.132 | 0.146 | 0.091 |
| NOD1           | 2 (1–3)          | 2 (1–3)          | 0.366            | 2 (1–3) | 2 (0–3) | 0.589 | 2 (1–3) | 2 (2–3) | 0.096 | 0.696 | 0.197 |
| NOD2           | 2 (0–3)          | 2 (1–3)          | 0.107            | 2 (0–3) | 2 (1–3) | 0.317 | 1 (1–2) | 2 (1–3) | 0.107 | 0.331 | 0.560 |
| TRL2           | 1 (0–3)          | 1 (0–2)          | 0.084            | 0 (0–3) | 1 (0–2) | 0.480 | 1 (0–2) | 1 (0–3) | 0.271 | 0.083 | 0.777 |
| TRL4           | 0 (0–2)          | 0 (0–2)          | 0.999            | 0 (0–2) | 0 (0–2) | 0.890 | 0 (0–3) | 1 (0–3) | 0.546 | 0.440 | 0.067 |

Data presented as median (minimum–maximum).

a,b Different letters represent statistically different distributions.

P<Wilcoxon test.

P<Kruskal Wallis test.

256
mediated inflammation, as the overexpression of NOD2 reduces clonal proliferation.\textsuperscript{7,8}

PPARG acts on sebocyte modulation. Its GLA/LA/OA-induced 5\textsuperscript{th} generation reduction may be the cause of the increase in lauric, myristic, and palmitic acids under equal therapy, suggesting the same role in NOD2-lowering effects in the IE.\textsuperscript{9}

GLA/LA/OA were used in Groups 2 and 3. Therefore, we suggest that their administration causes PPARG reduction in sebocytes in Group 2 and NOD2 in the IE of both Groups 2 and 3, reinforcing the hypothesis of beneficial supplementation with GLA/LA/OA for comedonal and cystic AV.\textsuperscript{9,10} Therefore, FAIs with great bactericidal potential could reduce the concentrations of Cutibacterium acnes and, thus, the expression of bacterium-activated receptors. Interestingly, isolated LM increased NOD2 labeling in HF, requiring further elucidative studies. As PPARG and NOD2 are inversely related to papules in Group 3, perhaps they can be recruited in the early stages of the dermatosis.

Therefore, it is concluded that daily administration of LM and/or GLA/LA/OA interferes with the pro-inflammatory markers in AV, and supplementation with GLA/LA/OA could be an adjuvant in the treatment of AV.

Financial support

This publication was made possible with the support from Fundo de Apoio à Dermatologia (Funaderm) da Sociedade Brasileira de Dermatologia, Galderma Brasil Ltda., São Paulo, SP, Brazil, and Arese Pharma Ltda., Valinhos, SP, Brazil.

Authors’ contributions

Clarissa Prati: Statistical analysis; approval of the final version of the manuscript; design and planning of the study; drafting and editing of the manuscript; collection, analysis, and interpretation of data; critical review of the literature.

Emily Ferreira Salles Pilar: Approval of the final version of the manuscript; collection, analysis, and interpretation of data; effective participation in research orientation.

Andre Cartel: Approval of the final version of the manuscript; collection, analysis, and interpretation of.

João Bayma Galvão Pitoni: Approval of the final version of the manuscript; collection, analysis, and interpretation of data.

Cidia Vasconcellos: Approval of the final version of the manuscript; effective participation in research orientation; critical review of the manuscript.

Adilson da Costa: Approval of the final version of the manuscript; design and planning of the study; drafting and editing of the manuscript; effective participation in research orientation; critical review of the manuscript.

Conflicts of interest

None declared.

References

1. Dreno B, Gollnick HP, Kang S, Thiboutot D, Bettoli V, Torres V, et al. Understanding innate immunity and inflammation in acne: implications for management. J Eur Acad Dermatol Venereol. 2015;29:3–11.

2. Zouboulis CC, Saborowski A, Boschnakov A, Zileuton, an oral 5\textsuperscript{th}lipoxigenase inhibitor, directly reduces sebum production. Dermatol. 2005;210:36–8.

3. Gollnick HP, Bettoli V, Lambert J, Araviiskaia E, Binic I, Dessinioti C, et al. A consensus-based practical and daily guide for the treatment of acne patients. J Eur Acad Dermatol Venereol. 2016;30:1480–90.

4. Dreno B, Bettoli V, Ochsendorf F, Layton A, Mabacken H, Degreef H, European Expert Group on Oral Antibiotics in Acne. European recommendations on the use or antibiotics for acne. Eur J Dermatol. 2004;12:391–9.

5. Costa A, Alchone MWA, Michalany NS, Lima HC. Acne vulgar: estudo piloto de avaliação do uso oral de ácidos graxos essenciais por meio de análises clínica, digital e histopatológica. An Bras Dermatol. 2007;82:129–34.

6. Rustin MHA. Dermatology. Postgrad Med J. 1990;66:894–905.

7. Grime CL, Arivananda D de Z, Melnyk JE, O’Shea EK. The innate immune protein Nod2 binds directly to MDP, a bacterial cell wall fragment. J Am Chem Soc. 2012;134:13535–7.

8. Velloso FJ, Sogayar MC, Correa RG. Expression and in vitro assessment of tumorigenicity for NOD1 and NOD2 receptors in breast cancer cell lines. BMC Res Notes. 2018;11:222.

9. Costa A, Siqueira Talarico A, Parra Duarte Cde O, Silva Pereira C, de Souza Weimann ET, Sabino de Matos I, et al. Evaluation of the quantitative and qualitative alterations in the fatty acid contents of the sebum of patients with inflammatory acne during treatment with systemic lymecycline and/or oral fatty acid supplementation. Dermatol Res Pract. 2013;2013:120475.

Clarissa Prati, Andre Cartel, João Bayma Galvão Pitoni, Cidia Vasconcellos, Adilson da Costa.

\( ^{a} \) Instituto de Assistência Médica ao Servidor Público Estadual, São Paulo, SP, Brazil.

\( ^{b} \) Hospital de Clínicas, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

\( ^{c} \) International Pediatric Clinics, Atlanta, GA, USA

\( ^{∗} \) Corresponding authors.

E-mail: cprati2018@gmail.com (C. Prati), adilson_costa@hotmail.com (A. Costa).

Received 8 September 2020; accepted 14 November 2020 available online 17 January 2022.

https://doi.org/10.1016/j.jabd.2020.11.016

0365-0596 © 2021 Published by Elsevier España, S.L.U. on behalf of Sociedade Brasileira de Dermatologia. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).